Submit Search
Upload
mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inbar_Mediclever
•
0 likes
•
529 views
Levi Shapiro
Follow
Synchronizing Reimbursement and Regulatory Activities by Amir Inbar, CEO, Mediclever.
Read less
Read more
Healthcare
Report
Share
Report
Share
1 of 18
Download now
Download to read offline
Recommended
mHealth Israel_Payers, Providers & Reimbursement_Amir Inbar_Mediclever
mHealth Israel_Payers, Providers & Reimbursement_Amir Inbar_Mediclever
Levi Shapiro
mHealth Israel_Rhoen Innovations_B2B2C Bootcamp_Dec 8, 2016
mHealth Israel_Rhoen Innovations_B2B2C Bootcamp_Dec 8, 2016
Levi Shapiro
The Future of Healthcare in Consumerism World
The Future of Healthcare in Consumerism World
CitiusTech
Healthcare Consumerism and Cost: Dispelling the Myth of Price Transparency
Healthcare Consumerism and Cost: Dispelling the Myth of Price Transparency
Health Catalyst
HM311 Ab103417 ch10
HM311 Ab103417 ch10
BealCollegeOnline
US Healthcare Reimbursement for MedTech & Digital Health
US Healthcare Reimbursement for MedTech & Digital Health
Levi Shapiro
Quality & Outcomes Framework (QOF)
Quality & Outcomes Framework (QOF)
CitiusTech
ICD-10 Transition Presentation: What Health Lawyers Need to Know
ICD-10 Transition Presentation: What Health Lawyers Need to Know
PYA, P.C.
Recommended
mHealth Israel_Payers, Providers & Reimbursement_Amir Inbar_Mediclever
mHealth Israel_Payers, Providers & Reimbursement_Amir Inbar_Mediclever
Levi Shapiro
mHealth Israel_Rhoen Innovations_B2B2C Bootcamp_Dec 8, 2016
mHealth Israel_Rhoen Innovations_B2B2C Bootcamp_Dec 8, 2016
Levi Shapiro
The Future of Healthcare in Consumerism World
The Future of Healthcare in Consumerism World
CitiusTech
Healthcare Consumerism and Cost: Dispelling the Myth of Price Transparency
Healthcare Consumerism and Cost: Dispelling the Myth of Price Transparency
Health Catalyst
HM311 Ab103417 ch10
HM311 Ab103417 ch10
BealCollegeOnline
US Healthcare Reimbursement for MedTech & Digital Health
US Healthcare Reimbursement for MedTech & Digital Health
Levi Shapiro
Quality & Outcomes Framework (QOF)
Quality & Outcomes Framework (QOF)
CitiusTech
ICD-10 Transition Presentation: What Health Lawyers Need to Know
ICD-10 Transition Presentation: What Health Lawyers Need to Know
PYA, P.C.
mHealth Israel_Reimbursement Bootcamp_Jan 2020
mHealth Israel_Reimbursement Bootcamp_Jan 2020
Levi Shapiro
HMOs and PPOs in USA (Healthcare Management Functions)
HMOs and PPOs in USA (Healthcare Management Functions)
Abdu Naf'an
ICD-10 Transition: What Health Lawyers Need to Know
ICD-10 Transition: What Health Lawyers Need to Know
PYA, P.C.
The Evolving Role of the Compliance Officer in the Age of Accountable Care
The Evolving Role of the Compliance Officer in the Age of Accountable Care
PYA, P.C.
Simple Strategies to Boost Billing Efficiency Post-Covid
Simple Strategies to Boost Billing Efficiency Post-Covid
ecare India
ICD-10 Is Really Here: What Does That Mean To Compliance Officers?
ICD-10 Is Really Here: What Does That Mean To Compliance Officers?
PYA, P.C.
MIPS APM for ACOs: A Hybrid Reimbursement Model
MIPS APM for ACOs: A Hybrid Reimbursement Model
CitiusTech
The Medical Advantage, Inc. - EMR & Meaningful Use
The Medical Advantage, Inc. - EMR & Meaningful Use
Walz Group, LLC.
Managing ACO Populations across the Continuum Financially and Clinically - Do...
Managing ACO Populations across the Continuum Financially and Clinically - Do...
Healthcare Network marcus evans
Impact of HEDIS on Health Plans
Impact of HEDIS on Health Plans
CitiusTech
Big Data Applications in Healthcare
Big Data Applications in Healthcare
PYA, P.C.
Decoding the Sunshine Act - What Exactly are Manufacturers Reporting and How ...
Decoding the Sunshine Act - What Exactly are Manufacturers Reporting and How ...
Vanessa Towning
Implementation of a Perioperative Surgical Home (PSH)
Implementation of a Perioperative Surgical Home (PSH)
Wellbe
Using the Perioperative Surgical Home as a Model to Implement CJR
Using the Perioperative Surgical Home as a Model to Implement CJR
Wellbe
PYA Highlights Next Steps of Meaningful Use
PYA Highlights Next Steps of Meaningful Use
PYA, P.C.
Carelife Deck v1
Carelife Deck v1
farhadcarelife
ICD-10 Transition Update: What Health Lawyers Need to Know
ICD-10 Transition Update: What Health Lawyers Need to Know
PYA, P.C.
Planning for Success with Clinical Integration
Planning for Success with Clinical Integration
Conifer Health Solutions
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...
PYA, P.C.
Meaningful Use Basics for Healthcare Professionals and Organizations
Meaningful Use Basics for Healthcare Professionals and Organizations
Jose Ivan Delgado, Ph.D.
Tensor flow usergroup 2016 (公開版)
Tensor flow usergroup 2016 (公開版)
Hiroki Nakahara
なにわTech20161215
なにわTech20161215
Natsutani Minoru
More Related Content
What's hot
mHealth Israel_Reimbursement Bootcamp_Jan 2020
mHealth Israel_Reimbursement Bootcamp_Jan 2020
Levi Shapiro
HMOs and PPOs in USA (Healthcare Management Functions)
HMOs and PPOs in USA (Healthcare Management Functions)
Abdu Naf'an
ICD-10 Transition: What Health Lawyers Need to Know
ICD-10 Transition: What Health Lawyers Need to Know
PYA, P.C.
The Evolving Role of the Compliance Officer in the Age of Accountable Care
The Evolving Role of the Compliance Officer in the Age of Accountable Care
PYA, P.C.
Simple Strategies to Boost Billing Efficiency Post-Covid
Simple Strategies to Boost Billing Efficiency Post-Covid
ecare India
ICD-10 Is Really Here: What Does That Mean To Compliance Officers?
ICD-10 Is Really Here: What Does That Mean To Compliance Officers?
PYA, P.C.
MIPS APM for ACOs: A Hybrid Reimbursement Model
MIPS APM for ACOs: A Hybrid Reimbursement Model
CitiusTech
The Medical Advantage, Inc. - EMR & Meaningful Use
The Medical Advantage, Inc. - EMR & Meaningful Use
Walz Group, LLC.
Managing ACO Populations across the Continuum Financially and Clinically - Do...
Managing ACO Populations across the Continuum Financially and Clinically - Do...
Healthcare Network marcus evans
Impact of HEDIS on Health Plans
Impact of HEDIS on Health Plans
CitiusTech
Big Data Applications in Healthcare
Big Data Applications in Healthcare
PYA, P.C.
Decoding the Sunshine Act - What Exactly are Manufacturers Reporting and How ...
Decoding the Sunshine Act - What Exactly are Manufacturers Reporting and How ...
Vanessa Towning
Implementation of a Perioperative Surgical Home (PSH)
Implementation of a Perioperative Surgical Home (PSH)
Wellbe
Using the Perioperative Surgical Home as a Model to Implement CJR
Using the Perioperative Surgical Home as a Model to Implement CJR
Wellbe
PYA Highlights Next Steps of Meaningful Use
PYA Highlights Next Steps of Meaningful Use
PYA, P.C.
Carelife Deck v1
Carelife Deck v1
farhadcarelife
ICD-10 Transition Update: What Health Lawyers Need to Know
ICD-10 Transition Update: What Health Lawyers Need to Know
PYA, P.C.
Planning for Success with Clinical Integration
Planning for Success with Clinical Integration
Conifer Health Solutions
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...
PYA, P.C.
Meaningful Use Basics for Healthcare Professionals and Organizations
Meaningful Use Basics for Healthcare Professionals and Organizations
Jose Ivan Delgado, Ph.D.
What's hot
(20)
mHealth Israel_Reimbursement Bootcamp_Jan 2020
mHealth Israel_Reimbursement Bootcamp_Jan 2020
HMOs and PPOs in USA (Healthcare Management Functions)
HMOs and PPOs in USA (Healthcare Management Functions)
ICD-10 Transition: What Health Lawyers Need to Know
ICD-10 Transition: What Health Lawyers Need to Know
The Evolving Role of the Compliance Officer in the Age of Accountable Care
The Evolving Role of the Compliance Officer in the Age of Accountable Care
Simple Strategies to Boost Billing Efficiency Post-Covid
Simple Strategies to Boost Billing Efficiency Post-Covid
ICD-10 Is Really Here: What Does That Mean To Compliance Officers?
ICD-10 Is Really Here: What Does That Mean To Compliance Officers?
MIPS APM for ACOs: A Hybrid Reimbursement Model
MIPS APM for ACOs: A Hybrid Reimbursement Model
The Medical Advantage, Inc. - EMR & Meaningful Use
The Medical Advantage, Inc. - EMR & Meaningful Use
Managing ACO Populations across the Continuum Financially and Clinically - Do...
Managing ACO Populations across the Continuum Financially and Clinically - Do...
Impact of HEDIS on Health Plans
Impact of HEDIS on Health Plans
Big Data Applications in Healthcare
Big Data Applications in Healthcare
Decoding the Sunshine Act - What Exactly are Manufacturers Reporting and How ...
Decoding the Sunshine Act - What Exactly are Manufacturers Reporting and How ...
Implementation of a Perioperative Surgical Home (PSH)
Implementation of a Perioperative Surgical Home (PSH)
Using the Perioperative Surgical Home as a Model to Implement CJR
Using the Perioperative Surgical Home as a Model to Implement CJR
PYA Highlights Next Steps of Meaningful Use
PYA Highlights Next Steps of Meaningful Use
Carelife Deck v1
Carelife Deck v1
ICD-10 Transition Update: What Health Lawyers Need to Know
ICD-10 Transition Update: What Health Lawyers Need to Know
Planning for Success with Clinical Integration
Planning for Success with Clinical Integration
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...
Meaningful Use Basics for Healthcare Professionals and Organizations
Meaningful Use Basics for Healthcare Professionals and Organizations
Viewers also liked
Tensor flow usergroup 2016 (公開版)
Tensor flow usergroup 2016 (公開版)
Hiroki Nakahara
なにわTech20161215
なにわTech20161215
Natsutani Minoru
Slide
Slide
Takefumi MIYOSHI
Synthesijer and Synthesijer.Scala in HLS-friends 201512
Synthesijer and Synthesijer.Scala in HLS-friends 201512
Takefumi MIYOSHI
Hls friends 20161122.key
Hls friends 20161122.key
Takefumi MIYOSHI
電波望遠鏡用の分光器をAltera SDK for OpenCL使ってサクッと作ってみた
電波望遠鏡用の分光器をAltera SDK for OpenCL使ってサクッと作ってみた
Hiroki Nakahara
HPCで使えそうなFPGA搭載AWS F1 インスタンス_20161218
HPCで使えそうなFPGA搭載AWS F1 インスタンス_20161218
HPCシステムズ株式会社
FPGAX2016 ドキュンなFPGA
FPGAX2016 ドキュンなFPGA
Hiroki Nakahara
なにわテック道0903
なにわテック道0903
Natsutani Minoru
なにわTech20160827
なにわTech20160827
Natsutani Minoru
自称IQ診断 --- いわゆる頭の体操
自称IQ診断 --- いわゆる頭の体操
HPCシステムズ株式会社
20161120_HPCでFPGAを使ってみたい_fpgastartup
20161120_HPCでFPGAを使ってみたい_fpgastartup
HPCシステムズ株式会社
1 акт
1 акт
Александр Веретельников
프릴리지『 http://x5.ana.kr 』 톡 w2015 ♡ 프릴리지판매, 프릴리지효과,프릴리지정품구입,프릴리지부작용,프릴리지지속시간
프릴리지『 http://x5.ana.kr 』 톡 w2015 ♡ 프릴리지판매, 프릴리지효과,프릴리지정품구입,프릴리지부작용,프릴리지지속시간
무우 단
프릴리지『 http://x5.ana.kr 』 톡 w2015 ♡ 프릴리지판매 ,프릴리지가격,프릴리지구입방법,프릴리지후불구입,프릴리지국산, ...
프릴리지『 http://x5.ana.kr 』 톡 w2015 ♡ 프릴리지판매 ,프릴리지가격,프릴리지구입방법,프릴리지후불구입,프릴리지국산, ...
무우 단
Jeová e o ministério pre mortal e a criação
Jeová e o ministério pre mortal e a criação
Élida Rolim
Gure lanbideak
Gure lanbideak
silviavielba
Virtual Reality Workshop (3/13/2017)
Virtual Reality Workshop (3/13/2017)
KR_Barker
Día del idioma
Día del idioma
Johan Chacon
El exilio babilonico
El exilio babilonico
ABIESER MACIAS RODAS
Viewers also liked
(20)
Tensor flow usergroup 2016 (公開版)
Tensor flow usergroup 2016 (公開版)
なにわTech20161215
なにわTech20161215
Slide
Slide
Synthesijer and Synthesijer.Scala in HLS-friends 201512
Synthesijer and Synthesijer.Scala in HLS-friends 201512
Hls friends 20161122.key
Hls friends 20161122.key
電波望遠鏡用の分光器をAltera SDK for OpenCL使ってサクッと作ってみた
電波望遠鏡用の分光器をAltera SDK for OpenCL使ってサクッと作ってみた
HPCで使えそうなFPGA搭載AWS F1 インスタンス_20161218
HPCで使えそうなFPGA搭載AWS F1 インスタンス_20161218
FPGAX2016 ドキュンなFPGA
FPGAX2016 ドキュンなFPGA
なにわテック道0903
なにわテック道0903
なにわTech20160827
なにわTech20160827
自称IQ診断 --- いわゆる頭の体操
自称IQ診断 --- いわゆる頭の体操
20161120_HPCでFPGAを使ってみたい_fpgastartup
20161120_HPCでFPGAを使ってみたい_fpgastartup
1 акт
1 акт
프릴리지『 http://x5.ana.kr 』 톡 w2015 ♡ 프릴리지판매, 프릴리지효과,프릴리지정품구입,프릴리지부작용,프릴리지지속시간
프릴리지『 http://x5.ana.kr 』 톡 w2015 ♡ 프릴리지판매, 프릴리지효과,프릴리지정품구입,프릴리지부작용,프릴리지지속시간
프릴리지『 http://x5.ana.kr 』 톡 w2015 ♡ 프릴리지판매 ,프릴리지가격,프릴리지구입방법,프릴리지후불구입,프릴리지국산, ...
프릴리지『 http://x5.ana.kr 』 톡 w2015 ♡ 프릴리지판매 ,프릴리지가격,프릴리지구입방법,프릴리지후불구입,프릴리지국산, ...
Jeová e o ministério pre mortal e a criação
Jeová e o ministério pre mortal e a criação
Gure lanbideak
Gure lanbideak
Virtual Reality Workshop (3/13/2017)
Virtual Reality Workshop (3/13/2017)
Día del idioma
Día del idioma
El exilio babilonico
El exilio babilonico
Similar to mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inbar_Mediclever
Presentation__Reimbursement Overview
Presentation__Reimbursement Overview
Kendrik Lechner
Prescription Medicines MMDR Reforms
Prescription Medicines MMDR Reforms
TGA Australia
Drug Approval & Reimbursement Processes
Drug Approval & Reimbursement Processes
Canadian Cancer Survivor Network
Requirements for reimbursement of new medical devices
Requirements for reimbursement of new medical devices
Mike Sanchez
New standards for registered pharmacies – sept 2012
New standards for registered pharmacies – sept 2012
GPhC
Clinical trial optimization
Clinical trial optimization
Barons Medical Consulting
Presentation: Recall of Therapeutic Goods
Presentation: Recall of Therapeutic Goods
TGA Australia
Update on Payment Reform and Changing Models
Update on Payment Reform and Changing Models
Jamie Christensen Palatnik
Developing a Practice Compliance Plan
Developing a Practice Compliance Plan
shelvan1967
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...
TGA Australia
Is ACO-Led Payment Reform Working?
Is ACO-Led Payment Reform Working?
Jamie Christensen Palatnik
A Seven Step Approach to a Clinically Integrated Network.pdf
A Seven Step Approach to a Clinically Integrated Network.pdf
PatWilson13
Value based commissioning flow chartv2
Value based commissioning flow chartv2
Primary Care Commissioning (PCC)
Presentation: Regulatory affairs - The Australian and International landscape
Presentation: Regulatory affairs - The Australian and International landscape
TGA Australia
Plan for Success Strategies to Align Reimbursement and Commercialization - OM...
Plan for Success Strategies to Align Reimbursement and Commercialization - OM...
April Bright
Webinar: Oncology Care Model - Introduction
Webinar: Oncology Care Model - Introduction
Centers for Medicare & Medicaid Services (CMS)
Price Transparency
Price Transparency
John Yeager
CPS Council Meeting - November 2016
CPS Council Meeting - November 2016
Kirsten Crawford
Delivering Care Under the MACRA Final Rule: Implementation Considerations and...
Delivering Care Under the MACRA Final Rule: Implementation Considerations and...
Epstein Becker Green
mHealth Israel_US Reimbursement_David Farber_King & Spalding
mHealth Israel_US Reimbursement_David Farber_King & Spalding
Levi Shapiro
Similar to mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inbar_Mediclever
(20)
Presentation__Reimbursement Overview
Presentation__Reimbursement Overview
Prescription Medicines MMDR Reforms
Prescription Medicines MMDR Reforms
Drug Approval & Reimbursement Processes
Drug Approval & Reimbursement Processes
Requirements for reimbursement of new medical devices
Requirements for reimbursement of new medical devices
New standards for registered pharmacies – sept 2012
New standards for registered pharmacies – sept 2012
Clinical trial optimization
Clinical trial optimization
Presentation: Recall of Therapeutic Goods
Presentation: Recall of Therapeutic Goods
Update on Payment Reform and Changing Models
Update on Payment Reform and Changing Models
Developing a Practice Compliance Plan
Developing a Practice Compliance Plan
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...
Is ACO-Led Payment Reform Working?
Is ACO-Led Payment Reform Working?
A Seven Step Approach to a Clinically Integrated Network.pdf
A Seven Step Approach to a Clinically Integrated Network.pdf
Value based commissioning flow chartv2
Value based commissioning flow chartv2
Presentation: Regulatory affairs - The Australian and International landscape
Presentation: Regulatory affairs - The Australian and International landscape
Plan for Success Strategies to Align Reimbursement and Commercialization - OM...
Plan for Success Strategies to Align Reimbursement and Commercialization - OM...
Webinar: Oncology Care Model - Introduction
Webinar: Oncology Care Model - Introduction
Price Transparency
Price Transparency
CPS Council Meeting - November 2016
CPS Council Meeting - November 2016
Delivering Care Under the MACRA Final Rule: Implementation Considerations and...
Delivering Care Under the MACRA Final Rule: Implementation Considerations and...
mHealth Israel_US Reimbursement_David Farber_King & Spalding
mHealth Israel_US Reimbursement_David Farber_King & Spalding
More from Levi Shapiro
Version Bravo- The Springboard for Navy SEAL entrepreneurship, cohort 003
Version Bravo- The Springboard for Navy SEAL entrepreneurship, cohort 003
Levi Shapiro
Radical Life Extension_Dr. Leon Peshkin_Dec 2023
Radical Life Extension_Dr. Leon Peshkin_Dec 2023
Levi Shapiro
Israel’s Life Science Hub 2023 English Abstract.pdf
Israel’s Life Science Hub 2023 English Abstract.pdf
Levi Shapiro
Gil Bashe FINN Partners: The Future of Digital Health – Nose Dive or Transfor...
Gil Bashe FINN Partners: The Future of Digital Health – Nose Dive or Transfor...
Levi Shapiro
Urgent Request and Call for Action for Ensuring Safety and Inclusivity at MIT
Urgent Request and Call for Action for Ensuring Safety and Inclusivity at MIT
Levi Shapiro
HLTH-2023-Digital-Catalouge.pdf
HLTH-2023-Digital-Catalouge.pdf
Levi Shapiro
Baptist Health- Engineering the Future of Healthcare
Baptist Health- Engineering the Future of Healthcare
Levi Shapiro
YEDA Techn Transfer at Weizmann Institute- Discord and Challenges in Academic...
YEDA Techn Transfer at Weizmann Institute- Discord and Challenges in Academic...
Levi Shapiro
HADASIT: Tech Transfer and More in Life Science
HADASIT: Tech Transfer and More in Life Science
Levi Shapiro
Presenting to Investors & the Media.pdf
Presenting to Investors & the Media.pdf
Levi Shapiro
Nissan Elimelech, Founder, Augmedics: How I Built the World's First XR Surgic...
Nissan Elimelech, Founder, Augmedics: How I Built the World's First XR Surgic...
Levi Shapiro
Beyeonics CEO, Ron Schneider, Advances in Medical XR
Beyeonics CEO, Ron Schneider, Advances in Medical XR
Levi Shapiro
XRHealth Founder, Miki Levy
XRHealth Founder, Miki Levy
Levi Shapiro
Digital Health in US Health Systems.pptx
Digital Health in US Health Systems.pptx
Levi Shapiro
Course Syllabus (Digital Rosh): The Future of Digital Medicine- Biology, Gene...
Course Syllabus (Digital Rosh): The Future of Digital Medicine- Biology, Gene...
Levi Shapiro
Alagene BioFoundry: Releasing the Genie Out of the Bottle
Alagene BioFoundry: Releasing the Genie Out of the Bottle
Levi Shapiro
Digital Health Ecosystem- 2022 3rd Quarter Report
Digital Health Ecosystem- 2022 3rd Quarter Report
Levi Shapiro
EU Medical Device Regulatory Framework_Dec, 2022
EU Medical Device Regulatory Framework_Dec, 2022
Levi Shapiro
FINN Partners Global State of Digital Health Q3 2022
FINN Partners Global State of Digital Health Q3 2022
Levi Shapiro
Digitally powered participant-directed studies- Strategy for Decentralized Ca...
Digitally powered participant-directed studies- Strategy for Decentralized Ca...
Levi Shapiro
More from Levi Shapiro
(20)
Version Bravo- The Springboard for Navy SEAL entrepreneurship, cohort 003
Version Bravo- The Springboard for Navy SEAL entrepreneurship, cohort 003
Radical Life Extension_Dr. Leon Peshkin_Dec 2023
Radical Life Extension_Dr. Leon Peshkin_Dec 2023
Israel’s Life Science Hub 2023 English Abstract.pdf
Israel’s Life Science Hub 2023 English Abstract.pdf
Gil Bashe FINN Partners: The Future of Digital Health – Nose Dive or Transfor...
Gil Bashe FINN Partners: The Future of Digital Health – Nose Dive or Transfor...
Urgent Request and Call for Action for Ensuring Safety and Inclusivity at MIT
Urgent Request and Call for Action for Ensuring Safety and Inclusivity at MIT
HLTH-2023-Digital-Catalouge.pdf
HLTH-2023-Digital-Catalouge.pdf
Baptist Health- Engineering the Future of Healthcare
Baptist Health- Engineering the Future of Healthcare
YEDA Techn Transfer at Weizmann Institute- Discord and Challenges in Academic...
YEDA Techn Transfer at Weizmann Institute- Discord and Challenges in Academic...
HADASIT: Tech Transfer and More in Life Science
HADASIT: Tech Transfer and More in Life Science
Presenting to Investors & the Media.pdf
Presenting to Investors & the Media.pdf
Nissan Elimelech, Founder, Augmedics: How I Built the World's First XR Surgic...
Nissan Elimelech, Founder, Augmedics: How I Built the World's First XR Surgic...
Beyeonics CEO, Ron Schneider, Advances in Medical XR
Beyeonics CEO, Ron Schneider, Advances in Medical XR
XRHealth Founder, Miki Levy
XRHealth Founder, Miki Levy
Digital Health in US Health Systems.pptx
Digital Health in US Health Systems.pptx
Course Syllabus (Digital Rosh): The Future of Digital Medicine- Biology, Gene...
Course Syllabus (Digital Rosh): The Future of Digital Medicine- Biology, Gene...
Alagene BioFoundry: Releasing the Genie Out of the Bottle
Alagene BioFoundry: Releasing the Genie Out of the Bottle
Digital Health Ecosystem- 2022 3rd Quarter Report
Digital Health Ecosystem- 2022 3rd Quarter Report
EU Medical Device Regulatory Framework_Dec, 2022
EU Medical Device Regulatory Framework_Dec, 2022
FINN Partners Global State of Digital Health Q3 2022
FINN Partners Global State of Digital Health Q3 2022
Digitally powered participant-directed studies- Strategy for Decentralized Ca...
Digitally powered participant-directed studies- Strategy for Decentralized Ca...
Recently uploaded
Thoothukudi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Thoothukudi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
Independent Call Girls Hyderabad 💋 9352988975 💋 Genuine WhatsApp Number for R...
Independent Call Girls Hyderabad 💋 9352988975 💋 Genuine WhatsApp Number for R...
Ahmedabad Call Girls
Erode Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Erode Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...
(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...
Ahmedabad Call Girls
kochi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
kochi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
Jaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthan
Jaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthan
indiancallgirl4rent
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
Bihar Sharif Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Bihar Sharif Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
Rajkot Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Rajkot Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
Nanded Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Nanded Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
Thrissur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Thrissur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
surat Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
surat Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Chandigarh
Sangli Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Sangli Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
Top 20 Famous Indian Female Pornstars Name List 2024
Top 20 Famous Indian Female Pornstars Name List 2024
Sheetaleventcompany
neemuch Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
neemuch Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
Ernakulam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ernakulam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Chandigarh
kozhikode Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
kozhikode Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
Mathura Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Mathura Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Call Girls Service
Recently uploaded
(20)
Thoothukudi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Thoothukudi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Independent Call Girls Hyderabad 💋 9352988975 💋 Genuine WhatsApp Number for R...
Independent Call Girls Hyderabad 💋 9352988975 💋 Genuine WhatsApp Number for R...
Erode Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Erode Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...
(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...
kochi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
kochi Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Jaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthan
Jaipur Call Girls 9257276172 Call Girl in Jaipur Rajasthan
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Bareilly Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Bihar Sharif Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Bihar Sharif Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Rajkot Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Rajkot Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Nanded Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Nanded Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Thrissur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Thrissur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
surat Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
surat Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Sangli Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Sangli Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Top 20 Famous Indian Female Pornstars Name List 2024
Top 20 Famous Indian Female Pornstars Name List 2024
neemuch Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
neemuch Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
nagpur Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ernakulam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Ernakulam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
kozhikode Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
kozhikode Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Mathura Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
Mathura Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
bhubaneswar Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inbar_Mediclever
1.
1 / 18
Copyright © 2016 Mediclever Ltd. Synchronizing Reimbursementand RegulatoryActivities Navigate your reimbursement pathway smarter. UK Office: • 27 Old Gloucester St., London WC1N 3AX • uk@mediclever.com • +44.208.099.7435 Israel Office: • 3b Lubetkin St., Herzliya 46409036 • il@mediclever.com • +972.9.835.6790 US Office: • 616 Corporate Way, Suite 2-4683, Valley Cottage, NY 10989 • us@mediclever.com • +1.845.570.2910 About Services Resources © Copyright 2016 Mediclever Ltd. All rights reserved. Neither this presentation nor any information it contains may be published, reproduced or used for any commercial purpose without prior written approval from Mediclever.
2.
2 / 18
Copyright © 2016 Mediclever Ltd. In a Nut Shell • We’ve successfully guided hundreds of life science clients from around the world in commercializing their medical devices, pharmaceuticals and apps. • We assume full responsibility for the entire process of obtaining reimbursement, hospital funding or out-of-pocket payment - from start to finish. • Learn more about our unique approach here. • Coordinate and manage the provision of Regulatory, Quality, and Clinical Research services. • Synchronize these activities with our clients’ reimbursement activities. OurPartners • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote
3.
3 / 18
Copyright © 2016 Mediclever Ltd. Reimbursement LandscapeOurPartners 1.Reimbursement Landscape a. Available reimbursement mechanisms The purpose of this step is to understand the current reimbursement environment relevant for your device/drug. a. Available reimbursement mechanisms: Are there any specific codes, payment rates and coverage policies that address the device or drug? If not, which new mechanisms need to be developed (e.g., a new code, an expansion of a coverage policy, a new payment rate to an existing code or all of the above)? • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote
4.
4 / 18
Copyright © 2016 Mediclever Ltd. Reimbursement LandscapeOurPartners 1.Reimbursement Landscape a. Available reimbursement mechanisms b. Decision Makers Healthcare Providers Payers The purpose of this step is to understand the current reimbursement environment relevant for your device/drug. a. Available reimbursement mechanisms: Are there any specific codes, payment rates and coverage policies that address the device or drug? If not, which new mechanisms need to be developed (e.g., a new code, an expansion of a coverage policy, a new payment rate to an existing code or all of the above)? b. Decision makers: • In case available existing mechanisms were identified in the above 1a, the main decision makers are healthcare providers. No need to approach payers. • In case new mechanisms need to be developed, the main decision makers are typically payers. • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote
5.
5 / 18
Copyright © 2016 Mediclever Ltd. Reimbursement LandscapeOurPartners The purpose of this step is to understand the current reimbursement environment relevant for your device/drug. a. Available reimbursement mechanisms: Are there any specific codes, payment rates and coverage policies that address the device or drug? If not, which new mechanisms need to be developed (e.g., a new code, an expansion of a coverage policy, a new payment rate to an existing code or all of the above)? b. Decision makers: • In case available existing mechanisms were identified in the above 1a, the main decision makers are healthcare providers. No need to approach payers. • In case new mechanisms need to be developed, the main decision makers are typically payers. c. Reimbursement strategy: An outline of the typical path for obtaining third-party reimbursement or any other sort of funding, including milestones and timelines, along with an initial reimbursement strategy for the device or drug in each of the selected countries. 1.Reimbursement Landscape a. Available reimbursement mechanisms c. Reimbursement strategy b. Decision Makers Healthcare Providers Payers • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote
6.
6 / 18
Copyright © 2016 Mediclever Ltd. Reimbursement LandscapeOurPartners 1.Reimbursement Landscape a. Available reimbursement mechanisms c. Reimbursement strategy b. Decision Makers Healthcare Providers Payers • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote C a s e S t u d y existing reimbursed codes. The company was left with one of two options: 1) Develop new reimbursement mechanisms for their product – a long and costly process, or: 2) Redesign the product to fit under existing pressure settings – another costly alternative requiring a new clinical study and regulatory clearance. Had the company conducted the Reimbursement Landscape in time, setting the appropriate pressure range would be easy and would mean having a reimbursed device in the market today. One of our clients developed and launched a product in the US market which included a pressure pump. Unfortunately, the pressure settings employed by the pump deviated from the allowable range specified under the
7.
7 / 18
Copyright © 2016 Mediclever Ltd. Regulatory LandscapeOurPartners 1.Reimbursement Landscape a. Available reimbursement mechanisms c. Reimbursement strategy b. Decision Makers Healthcare Providers Payers 2.Regulatory Landscape • Regulatory status • Device classification • Intended use & indications for use • Regulatory route Class III Class II Class I US Class I* Class I Class IIa Class IIb Class III EU • In parallel, or immediately after the Reimbursement Landscape Report is submitted, our partners provide the Regulatory Landscape Report to determine the product’s classification, intended use, indications for use and the anticipated regulatory route. • Sometimes regulatory status and classification are different between EU and US, and this needs to be taken into account when formulating regulatory, reimbursement and marketing strategies. • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote * Non-sterile without measuring function
8.
8 / 18
Copyright © 2016 Mediclever Ltd. Regulatory LandscapeOurPartners 1.Reimbursement Landscape a. Available reimbursement mechanisms c. Reimbursement strategy b. Decision Makers Healthcare Providers Payers 2.Regulatory Landscape • Regulatory status • Device classification • Intended use & indications for use • Regulatory route Class III Class II Class I US Class I* Class I Class IIa Class IIb Class III EU • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote * Non-sterile without measuring function C a s e S t u d y One of our clients asked us to start working on their reimbursement strategy after applying for, and receiving, the regulatory clearance. Unfortunately, the wording that was used in the regulatory application substantially decreased the likelihood of reimbursement. Consequently, the company re-applied for the regulatory clearance, this time, with a modified indication for use. Needless to say, this delayed the launch of the product resulting in substantial loss to the company. In this stage we make sure both reimbursement and regulatory strategies are aligned.
9.
9 / 18
Copyright © 2016 Mediclever Ltd. Preparations for Clinical Study OurPartners 1.Reimbursement Landscape a. Available reimbursement mechanisms c. Reimbursement strategy b. Decision Makers Healthcare Providers Payers At the next stage, when the company prepares for its clinical study (if needed, see chart below), it typically: • Implements the relevant parts of its Quality Management System (e.g., Design Controls and other QS aspects essential for US and EU pre-study compliance). • Writes its clinical study protocol. 2.Regulatory Landscape • Regulatory status • Device classification • Intended use & indications for use • Regulatory route Class III Class II Class I US Class I* Class I Class IIa Class IIb Class III EU 5.Clinical Study Protocol •Review and/or write protocol 3.Quality Management System • Design Control procedures • Other QS aspects essential for US and EU pre- study compliance • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote
10.
10 / 18
Copyright © 2016 Mediclever Ltd. Reimbursement PlanningOurPartners 1.Reimbursement Landscape a. Available reimbursement mechanisms c. Reimbursement strategy b. Decision Makers Healthcare Providers Payers Prior to initiating a clinical study, we plan how to generate the required reimbursement-related ‘evidence’, from the identified Decision Makers’ (i.e. Healthcare Providers’ / Payers’) perspective: a. Value Story: Highlights the clinical AND economic benefits of the new product. b. Economic Model: Quantifies the economic benefit, allows for sensitivity analysis and utilized as a pricing tool. c. Reimbursement Related Parameters: Integrated in the study protocol. d. Stakeholders’ Feedback: Used to validate decision makers’ agreement to pay for the product based on the presented plan. a. Value story b. Economic model c. Reimbursement issues for clinical study protocol d. Stakeholders’ feedback 4.Reimbursement Planning 2.Regulatory Landscape • Regulatory status • Device classification • Intended use & indications for use • Regulatory route Class III Class II Class I US Class I* Class I Class IIa Class IIb Class III EU 5.Clinical Study Protocol •Review and/or write protocol 3.Quality Management System • Design Control procedures • Other QS aspects essential for US and EU pre- study compliance • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote
11.
11 / 18
Copyright © 2016 Mediclever Ltd. Reimbursement PlanningOurPartners 1.Reimbursement Landscape a. Available reimbursement mechanisms c. Reimbursement strategy b. Decision Makers Healthcare Providers Payers a. Value story b. Economic model c. Reimbursement issues for clinical study protocol d. Stakeholders’ feedback 4.Reimbursement Planning 2.Regulatory Landscape • Regulatory status • Device classification • Intended use & indications for use • Regulatory route Class III Class II Class I US Class I* Class I Class IIa Class IIb Class III EU 5.Clinical Study Protocol •Review and/or write protocol 3.Quality Management System • Design Control procedures • Other QS aspects essential for US and EU pre- study compliance • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote C a s e S t u d y One of our clients developed clinical data for their product and invited us to help them develop specific reimbursement mechanisms for it. All payers were impressed by the developed clinical 'evidence', but wanted the company to also present data regarding a few economic aspects. Since these economic aspects were not observed during the company's previous clinical trial, the company had to perform a new trial to gather the requested data. Had the company thought about its reimbursement strategy prior to initiating the clinical trials, those economic aspects could have been easily integrated into their previous trials making the investment in a new trial, and the delay in the sale of their product, redundant.
12.
12 / 18
Copyright © 2016 Mediclever Ltd. Clinical StudyOurPartners 1.Reimbursement Landscape a. Available reimbursement mechanisms c. Reimbursement strategy b. Decision Makers Healthcare Providers Payers a. Value story b. Economic model c. Reimbursement issues for clinical study protocol d. Stakeholders’ feedback 4.Reimbursement Planning • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote 2.Regulatory Landscape • Regulatory status • Device classification • Intended use & indications for use • Regulatory route Class III Class II Class I US Class I* Class I Class IIa Class IIb Class III EU 5.Clinical Study Protocol •Review and/or write protocol 3.Quality Management System • Design Control procedures • Other QS aspects essential for US and EU pre- study compliance 6.Perform Clinical Study •Clinical Eval. Report Now, the clinical study may be conducted and the resulting ‘evidence’, substantiating the claims in the Value Story, should be published. The Clinical Evaluation Report (CER) should now be prepared, based on official European guidance. CER may also be useful for US submissions.
13.
13 / 18
Copyright © 2016 Mediclever Ltd. QMS CompletionOurPartners 1.Reimbursement Landscape a. Available reimbursement mechanisms c. Reimbursement strategy b. Decision Makers Healthcare Providers Payers a. Value story b. Economic model c. Reimbursement issues for clinical study protocol d. Stakeholders’ feedback 4.Reimbursement Planning • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote At this stage, if the company has not already done so, the quality management system can be completed to ensure it complies with US and/or European requirements. 2.Regulatory Landscape • Regulatory status • Device classification • Intended use & indications for use • Regulatory route Class III Class II Class I US Class I* Class I Class IIa Class IIb Class III EU 5.Clinical Study Protocol •Review and/or write protocol 3.Quality Management System • Design Control procedures • Other QS aspects essential for US and EU pre- study compliance 6.Perform Clinical Study •Clinical Eval. Report 7.Quality Manag. System •FDA QSR / ISO 13485
14.
14 / 18
Copyright © 2016 Mediclever Ltd. Regulatory ApplicationOurPartners 1.Reimbursement Landscape a. Available reimbursement mechanisms c. Reimbursement strategy b. Decision Makers Healthcare Providers Payers a. Value story b. Economic model c. Reimbursement issues for clinical study protocol d. Stakeholders’ feedback 4.Reimbursement Planning • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote The company may now submit the Technical File or the Design Dossier (in Europe) or apply for FDA Clearance / Approval (in the US). If granted, it could start selling its products. To obtain reimbursement, see the next slide… 2.Regulatory Landscape • Regulatory status • Device classification • Intended use & indications for use • Regulatory route Class III Class II Class I US Class I* Class I Class IIa Class IIb Class III EU 5.Clinical Study Protocol •Review and/or write protocol 3.Quality Management System • Design Control procedures • Other QS aspects essential for US and EU pre- study compliance 6.Perform Clinical Study •Clinical Eval. Report 7.Quality Manag. System •FDA QSR / ISO 13485 8.Prep. / App. •Design dossier •PMA •510(k) •Technical file
15.
15 / 18
Copyright © 2016 Mediclever Ltd. 1.Reimbursement Landscape a. Available reimbursement mechanisms c. Reimbursement strategy b. Decision Makers 6.Perform Clinical Study •Clinical Eval. Report 7.Quality Manag. System •FDA QSR / ISO 13485 8.Prep. / App. •Design dossier •PMA •510(k) •Technical file 9.Implementation a. User base, Obtain stakeholders’ support b. Utilize existing reimbursement mechanisms or: c. Apply for new reimbursement mechanisms a. Value story b. Economic model c. Reimbursement issues for clinical study protocol d. Stakeholders’ feedback 4.Reimbursement Planning Reimbursement Application Healthcare Providers Payers • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote In case we identified existing reimbursement mechanisms (Codes, Coverage, Payment) in Step 1 (Reimbursement Landscape), we • Compile the Value Story, Economic Model and the published ‘evidence’ into a dossier that serves as a sales tool under existing reimbursement mechanisms.
16.
16 / 18
Copyright © 2016 Mediclever Ltd. 1.Reimbursement Landscape a. Available reimbursement mechanisms c. Reimbursement strategy b. Decision Makers 6.Perform Clinical Study •Clinical Eval. Report 7.Quality Manag. System •FDA QSR / ISO 13485 8.Prep. / App. •Design dossier •PMA •510(k) •Technical file 9.Implementation a. User base, Obtain stakeholders’ support b. Utilize existing reimbursement mechanisms or: c. Apply for new reimbursement mechanisms a. Value story b. Economic model c. Reimbursement issues for clinical study protocol d. Stakeholders’ feedback 4.Reimbursement Planning Reimbursement Application Healthcare Providers Payers • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote In case we identified existing reimbursement mechanisms (Codes, Coverage, Payment) in Step 1 (Reimbursement Landscape), we • Compile the Value Story, Economic Model and the published ‘evidence’ into a dossier that serves as a sales tool under existing reimbursement mechanisms. Otherwise: • After verifying a sufficient user-base and support from the medical community, we will apply for new codes, coverage policies and favorable payment rates.
17.
17 / 18
Copyright © 2016 Mediclever Ltd. Thank you for Reviewing • Additional Free Articles • Speak with a Reimbursement Expert • Get our Quote To access additional articles, speak with one of our reimbursement consultants or receive a formal quote for our services, use the links on the top right corner. UK Office: • 27 Old Gloucester St., London WC1N 3AX • uk@mediclever.com • +44.208.099.7435 Israel Office: • 3b Lubetkin St., Herzliya 46409036 • il@mediclever.com • +972.9.835.6790 US Office: • 616 Corporate Way, Suite 2-4683, Valley Cottage, NY 10989 • us@mediclever.com • +1.845.570.2910 • Coordinate a meeting with a reimbursement consultant during the J.P. Morgan Annual Healthcare Conference / Biotech Showcase: January 9-13, 2017. San Francisco, CA
18.
18 / 18
Copyright © 2016 Mediclever Ltd.
Download now